Immpact's bispecific CAR T-cell therapy IMPT-314 cleared to enter clinic for B-cell lymphoma
Jan. 25, 2023
Immpact Bio USA Inc. has announced clearance of its IND application by the FDA for IMPT-314, a bispecific OR-Gate autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell antigens CD19 and CD20.
